The Potential of Proteolytic Chimeras as Pharmacological Tools and Therapeutic Agents
The induction of protein degradation in a highly selective and efficient way by means of druggable molecules is known as targeted protein degradation (TPD). TPD emerged in the literature as a revolutionary idea: a heterobifunctional chimera with the capacity of creating an interaction between a prot...
Main Authors: | Bernat Coll-Martínez, Antonio Delgado, Bernat Crosas |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2020-12-01
|
Series: | Molecules |
Subjects: | |
Online Access: | https://www.mdpi.com/1420-3049/25/24/5956 |
Similar Items
-
Proteolysis targeting chimeras (PROTACs) in cancer therapy
by: Alberto Ocaña, et al.
Published: (2020-09-01) -
From Conception to Development: Investigating PROTACs Features for Improved Cell Permeability and Successful Protein Degradation
by: Carlotta Cecchini, et al.
Published: (2021-04-01) -
Targeting the Ubiquitin-Proteasome System for Cancer Therapeutics by Small-Molecule Inhibitors
by: Gabriel LaPlante, et al.
Published: (2021-06-01) -
Discovery of the first potent proteolysis targeting chimera (PROTAC) degrader of indoleamine 2,3-dioxygenase 1
by: Mingxing Hu, et al.
Published: (2020-10-01) -
How the 26S Proteasome Degrades Ubiquitinated Proteins in the Cell
by: Bernat Coll-Martínez, et al.
Published: (2019-08-01)